New cocktail aims to stall pancreatic cancer after chemo
NCT ID NCT03404960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding an immunotherapy drug (ipilimumab or nivolumab) to niraparib, a targeted therapy, can prevent advanced pancreatic cancer from growing. It enrolled 104 adults whose cancer had not worsened after platinum-based chemotherapy. The goal was to see how long the cancer stayed under control and whether the combination was safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib plus either ipilimumab or nivolumab
What this could lead to
If successful, this combination could offer a new treatment option to keep advanced pancreatic cancer from growing for longer after initial chemotherapy.
What could go wrong
This is an early-phase, completed trial with only 104 participants, so results may not apply broadly. Combining drugs also raises the risk of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States